Mycophenolate mofetil in kidney transplantation

Current Opinion in Nephrology and Hypertension

Volumn 5, Issue 6, 1996, Pages 508-513

  Lui, Sing Leung ^a   Halloran, Philip F ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ANEMIA; COST; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; LEUKOPENIA; NAUSEA; PRIORITY JOURNAL; REVIEW; VOMITING;

ACUTE DISEASE; ANIMALS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; SAFETY; TREATMENT OUTCOME;

EID: 0030449460     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199611000-00009     Document Type: Review

References (54)

1. Allison AC, Eugui EM, Sollinger HW: Mycophenolate mofetil (RS-61443): mechanisms of action and effects In transplantation. Transplant Rev 1993, 7:129-139.
2. Wu JC: Mycophenolate mofetil: molecular mechanisms of action. In Perspectives in drug discovery and design. 2nd edn. Edited by Sigal NH, Wyvratt MJ. Leiden: ESCOM Science Publishers; 1994:185-204.
3. Sollinger HW: Mycophenolate mofetil. Kidney Int 1995, 48(suppl 2): S14-S17. This is an excellent review which summarizes the early experimental and clinical studies on MMF.
4. Ransom JT: The mechanism of action of mycophenolate mofetil. Ther Drug Monit 1995, 17:681-684. This is an excellent updated review on the mechanism of action of MMF.
5. Shaw LM, Sollinger HW, Halloran P, Morris RE, Yatscoff RW, Ransom J, Tsina I, Keown P, Holt DW, Lieberman R et al.: Mycophenolate mofetil: a report of the consensus panel. Ther Drug Monit 1995, 17:690-699 This report summarizes the current state of knowledge of the mechanism of action, pharmacokinetics and pharmacodynamics, therapeutic drug monitoring and clinical experience of MPA.
6. Nowak I, Shaw LM: Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995, 41:1011-1017. This study shows that MPA is extensively bound to human serum albumin and suggests that the pharmacological activity of MPA is a function of the unbound drug fraction.
7. Sweeney MJ, Hoffman DH, Esterman MA: Metabolism and biochemistry of mycophenolic acid. Cancer Res 1972, 32:1803-1809.
8. Shaw LM, Nowak I: Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit 1995, 17:685-689. This is an excellent review of the pharmacokinetic features of MPA.
9. Gosio B: Ricerche batteriologiche e chimiche sulle atterazion del mais; contributo alletiologia della pellagra. Igiene Sanita Pubbl Ann 1896, 7:825.
10. Mitsui A, Suzuki S: Immunosuppressive effect of mycophenolic acid. J Antibiot (Tokyo) 1969, 22:358-363.
11. Franklin TJ, Cook JM: The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969, 113:515-524.
12. Giblett ER, Anderson JE, Cohen F, Meuwissen HJ: Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972, 11:1067-1069.
13. Allison AC, Hovi T, Watts RWE, Webster ADB: Immunological observations on patients with the Lesch-Nyhan syndrome, and on the role of de novo purine synthesis in lymphocyte transformation. Lancet 1975, ii:1179-1183.
14. Eugui EM, Allison AC: Immunosuppressive activity of mycophenolate mofetil. Proc Natl Acad Sci USA 1993, 685:309-329.
15. Allison AC, Eugui EM: Immunosuppressive and long-acting anti-inflammatory activity of mycophenolic acid and derivative, RS-61443. Br J Rheumatol 1991, 20(suppl 2):57-61.
16. Schiff MH, Goldblum R, Rees MMC: 2-Morpholino-ethyl mycophenolic acid (ME-MPA) in the treatment of refractory rheumatoid arthritis (RA). Arthritis Rheum 1990, 33(suppl 9): 155.
17. Lynch WS, Roenick JR: Mycophenolic acid for psoriasis. Arch Dermatol 1977, 113:1203-1208.
18. Epinette WW, Parker CM, Jones EL, Griest MC: Mycophenolic acid for psoriasis: a review of pharmacology, long-term efficacy and safety. J Am Acad Dermatol 1987, 17:962-971.
19. Lee WA, Gu L, Miksztal AR, Chu N, Leung K, Nelson PH: Bioavailability improvement of mycophenolic acid through amino ester derivitization. Pharmacol Res 1990, 7:161-166.
20. Sintchak MD, Fleming MA, Futer O, Raybuck SA, Chambers SP, Caron PR, Murcko MA, Wilson KP: Structure and mechanism of Inosine monophosphate deydrogenase in complex with the immunosuppressant mycophenolic acid. Cell 1996, 85:921-930. This paper demonstrates the relationship between MPA and IMPDH at the molecular level and shows that MPA inhibits IMPDH by acting as a replacement for the nicotinamide portion of the nicotinamide adenine dinucleotide cofactor and a catalytic water molecule.
21. Allison AC, Eugui EM: The design and development of an immunosuppressive drug, mycophenolate mofetil. Semin Immunopathol 1993, 14:353-380.
22. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K: Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990, 265:5292-5295.
23. Nagai M, Natsumeda Y, Weber G: Proliferation-linked regulation of the type II IMP dehydrogenase gene in human normal lymphocytes and HL-60 leukemic cells. Cancer Res 1992, 52:258-261.
24. Carr SF, Papp E, Wu JC, Natsumeda Y: Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993, 268:27286-27290.
25. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM: Mycophenolic acid and Brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993, 25(suppl 2):67-70.
26. Heemann U, Azuma H, Hamar P, Schmid C, Tilney N, Philipp T: Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts. Transplant Immunol 1996, 4:64-67. This study found that treatment with MMF resulted in a marked reduction in leucocylic infiltration in the rejecting rat kidney allograft, probably because of decreased expression of adhesion molecules on the lymphocyte surface.
27. Allison AC, Almquist SJ, Muller CD, Eugui EM: In vitro immunosuppressive effects of mycophenolic acid and an ester prodrug, RS-61443. Transplant Proc 1991, 23(suppl 2):10-14.
28. Eugui EM, Almquist S, Muller CD, Allison AC: Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991, 33:161-173.
29. Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice. Scand J immunol 1991, 33:175-183.
30. Laurent AF, Dumont S, Poindron P, Muller CD: Mycophenolic acid suppresses protein N-linked glycosylation in human monocytes and their adhesion to endothelial cells and to some substrates. Exp Hematol 1996, 24:59-67. This study shows that in-vitro MPA decreases the attachment of monocytes to endothelial cells, which might explain partly its beneficial effects in the prevention of organ graft rejection.
31. Senda M, Delustro B, Eugui E, Natsumeda Y: Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995, 60:1143-1148. This study demonstrates that MPA blocks inducible nitric oxide synthetase in rodent brain vasculer endothelial cells by depleting GTP through inhibiting IMPDH activity. This might represent another mode of action of MPA.
32. Lemster B, Woo J, Strednak J, Wang SC, Todo S, Starzl TE, Thomson AW: Cytokine gene expression in murine lymphocytes activated in the presence of FK506, bredinin, mycophenolic acid, or Brequinar sodium. Transplant Proc 1992, 24:2845-2846.
33. Dayton JS, Turka LA, Thompson CB, Mitchell BS: Comparison of the effects of mizoribine with those of azathioprine 6-mercaptopurine and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1992, 41:671-676.
34. Halloran PF, Urmson J, Vincent D, Lui SL: Mycophenolate mofetil (MMF) inhibits cytokine production by prevention of clonal expansion [Abstract]. American Society of Transplant Physicians 15th Annual Meeting, Dallas Texas, May 1996, 1996:210.
35. Eugui EM, Mirkovich A, Allison AC: Lymphocyte-selective antiproliferative and Immunosuppressive activity of mycophenolic acid and its morpholinoethyl ester (RS-61443) in rodents. Transplant Proc 1991, 23(suppl 2):15-18.
36. Kimball JA, Pescovitz MD, Book BK, Norman DJ: Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995, 60:1379-1383. This study provides the first evidence that MMF significantly inhibits the responses of human B cells to antigen in vivo.
37. Morris RE, Hoyt EG, Eugui EM, Allison AC: Transplantation and its immunology: prolongation of rat heart allograft survival by RS-61443. Surg Forum 1989, 7:337-338.
38. Morris RE, Hoyt EG, Murphy MP, Eugui EM, Allison AC: Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T and B cell purine synthesis. Transplant Proc 1990, 22:1659-1662.
39. Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC: RS-61443 - a new, potent immunosuppressive agent. Transplantation 1991, 51:27-31.
40. Platz KP, Bechstein WO, Eckhoff DE, Suzuki Y, Sollinger HW: RS-61443 reverses acute allograft rejection in dogs. Surgery 1991, 110:736-740.
41. Knechtle SJ, Wang J, Burlingham WJ, Beeskau M, Subramanian R, Sollinger HW: The influence of RS-61443 on antibody-mediated reaction. Transplantation 1992, 53:699-701.
42. Benhaim P, Anthony JP, Lin LYT, McCalmont TH, Mathes SJ: A long-term study of allogeneic rat hindlimb transplants immunosuppressed with RS-61443. Transplantation 1993, 56:911-917.
43. Räisänen-Sokolowski A, Vuoristo P, Myllärniemi M, Yilmaz S, Kallio E, Häyry P: Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transplant Immunol 1995, 3:342-351. This study shows that MMF inhibits the histopathological changes of chronic rejection in a rat model by reducing the immune resoponse and replication of smooth muscle cells.
44. Gregory CR, Huang X, Pratt RE, Dzau VJ, Shorthouse R, Billingham ME, Morris RE: Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995, 59:655-661.
45. Azuma H, Binder J, Heemann U, Schmid C, Tullius SG, Tilney NL: Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995, 59:460-466.
46. Sollinger HW, Deierhoi MH, Belzer FO, Diethelm AG, Kauffman RS: RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 1992, 53:428-432.
47. Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS, Klintmalm GB, McDiarmid SV, Roberts J, Rosenthal JT, Tomlanovich SJ: RS-61443 (mycophenolate mofetil): a multicenter study. Ann Surg 1992, 216:513-519.
48. US Renal Transplant Mycophenolate Mofetil Study Group (Sollinger HW): Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995, 60:225-232. This multicentre trial compared the efficacy and safety of MMF with azathioprine for the prevention of acute rejection in renal transplant patients, and showed that MMF significantly reduces the rate of biopsy-proved rejection or treatment failure during the first 6 months after transplantation.
49. European Mycophenolate Mofetil Study Group: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995, 345:1321-1325. This multicentre trial compared the efficacy and safety of MMF with placebo for the prevention of acute rejection in renal transplant patients, and showed that the rate of biopsy-proved rejection or treatment failure during the first 6 months after transplantation in the MMF-treated groups was significantly lower than the placebo-treated group.
50. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996, 61:1029-1037. This study, carried out in North America, Europe and Australia shows that treatment with MMF is associated with a significantly lower rate of treatment failure compared with azathioprine during the first six months following renal transplant.
51. The International MMF Renal Transplant Study Group: A pooled analysis of three randomized double-blind clinical studies in prevention of rejection with mycophenolate mofetil in renal allograft recipients. Transplantation (in press). This paper pooled the data from the three multicentre trials of MMF in the prevention of acute rejection in renal transplant recipients and confirmed the efficacy and safety of MMF at 1 year after transplantation.
52. The Mycophenolate Mofetil Renal Refractory Rejection Study Group: Mycophenolate mofetil for the treatment of refractory, acute, cellular renal transplant rejection. Transplantation 1996, 61:722-729. This study demonstrated that MMF is probably effective in treating refractory acute rejection in renal transplantation although the difference between the treatment and the control groups in this study did not reach statistical significance, probably because of inadequate sample size.
53. Broski AP, Halloran PF: Clinical use of immunosuppressants in transplantation. In Perspectives in drug discovery and design. 2nd edn. Edited by Sigal NH, Wyvratt MJ. Leiden: ESCOM Science Publishers; 1994:3-24.
54. Sullivan SD: An economic evaluation of MMF for prevention of acute renal allograft rejection following primary cadaveric transplantation [Abstract]. American Society of Transplant Physicians, 15th Annual Meeting; Dallas, Texas. May 1996. 1996:128.